Intellectual Property

Currently, EnGeneIC is the sole owner of over 435 granted patents (19 families) world-wide and this covers the complete EDV technology for development of cancer therapeutics and viral vaccines. All patents have been developed in-house and further new patent applications are being filed covering new families related to the EDV technology. Since EnGeneIC’s inception in 2001, Foley and Lardner LLP (Washington DC, USA) have been the law firm responsible for the EnGeneIC IP portfolio.

In June 2015, Thompson Reuters presented an Award to EnGeneIC for being the most innovative Biotech company in Australia based on largest number and potential impact of granted patents.